Table of Content

1. Introduction to Oncolytic Virus Therapy
1.1 Overview
1.2 Need of Oncolytic Virus Immunotherapy


2. Globally Approved Oncolytic Virus Immunotherapies
2.1 Commercially Approved Therapies
2.2 FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME


3. Global Oncolytic Virus Immunotherapies Clinical Trials Overview
3.1 By Phase
3.2 By Country
3.3 By Company
3.4 By Indication
3.5 By Priority Status
3.6 Patient Segment


4. Global Oncolytic Virus Immunotherapy Market Trend & Developments
4.1 Current Market Outline
4.2 Future Market Forecast


5. Global Oncolytic Virus Immunotherapy Market Trends By Region
5.1 South Korea
5.2 Japan
5.3 US
5.4 Europe
5.5 UK
5.6 China
5.7 Australia


6. Global Oncolytic Virus Immunotherapy Market Trends By Indications
6.1 Melanoma
6.2 Head & Neck Cancer
6.3 Glioma
6.4 Pancreatic Cancer
6.5 Ovarian Cancer
6.6 Lymphoma
6.7 Lung Cancer
6.8 Breast Cancer
6.9 Prostate Cancer
6.10 Hepatocellular carcinoma


7. Global Oncolytic Viruses Immunotherapies Clinical Trials By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III
7.7 Registered


8. Marketed Oncolytic Viruses Immunotherapies Clinical Insight


9. Global Oncolytic Virus Immunotherapy - Availability, Dosage & Price Analysis
9.1 Imlygic
9.1.1 Overview & Patent Insights
9.1.2 Pricing & Dosage

9.2 Oncorine (H101)
9.2.1 Overview
9.2.2 Pricing & Dosage

9.3 Delytact
9.3.1 Overview
9.3.2 Pricing & Dosage


10. Platforms used for Developing Advanced Oncolytic Virus Immunotherapy
10.1 KaliVir VET Backbone Technology
10.2 Calidi’s Platform Technology
10.3 RenovoRx TAMP Platform
10.4 ValoTx PeptiCRAd
10.5 ValoTx PeptiVAX / PeptiENV / PeptiBAC
10.6 Transgene’s Invir.IO Platform
10.7 Transgene’s myvac Platform
10.8 Imugene’s CF33 Technology
10.9 EpicentRx AdAPT Platform
10.10 Genelux’s Choice Discovery Platform


11. Oncolytic Virus Immunotherapy Combinations with Other Therapeutic Agents
11.1 Oncolytic Virus Immunotherapy with Nano materials
11.2 Oncolytic Virus Immunotherapy with Chemotherapeutic Drugs
11.3 Oncolytic Virus Immunotherapy with Peptides
11.4 Oncolytic Virus Immunotherapy with Targeted Immunotherapies


12. Global Oncolytic Virus Immunotherapy Market Dynamics
12.1 Market Drivers
12.2 Market Challenges



13. Competitive Landscape
13.1 AdCure Bio
13.2 Beijing SyngenTech
13.3 BioVex Inc. (Amgen)
13.4 Calidi Biotherapeutics
13.5 Genelux Corporation
13.6 Immvira Pharma
13.7 Jennerex Biotherapeutics
13.8 KaliVir
13.9 Lokon Pharma
13.10 Oncolys BioPharma
13.11 PsiOxus Therapeutics (Akamis Bio)
13.12 Seneca Therapeutics
13.13 Shanghai Sunway Biotech
13.14 Takara Bio
13.15 TILT Biotherapeutics
13.16 Transgene
13.17 Virogin Biotech



List of Tables

Table 2-1: Approved Oncolytic Virus Immunotherapies

Table 5-1: US – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 5-2: Europe – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 6-1: Melanoma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-2: Head & Neck Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-3: Glioma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-4: Pancreatic Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-5: Ovarian Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-6: Lung Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-7: Breast Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy

Table 9-1: Imlygic - Recommended Dose & Schedule